To the central content area :::
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Lin,Jung Chin Lin,Jung Chin Charlene Yang 02-2655-7918 4F, NO. 3-2, PARK ST., NANGANG DIST.,TAIPEI CITY, TAIWAN 2016/09/26
Industry Main Business
Biotechnology and Medical Care Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of CNS and inflammatory diseases. The company is also actively engaged in scientific licensing and collaboration of first-in-class drug development. Lumosa has an experienced and well-integrated R&D and Business Development team; consist of professionals in chemical development, CMC, preclinical development, translational research, clinical development, regulatory affairs and project management, as well as intellectual property and business development.
Market Information ( 2023/10/04 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
117.366 61.00  60.20  60.40  -0.60  106 N/A N/A
Trading method Fun
price or
on T day
Announcement of Irregularity
TPEx measures
With warrants Can be shorted or margined? Detail
Normal N N N N N Today History
Financial Reports
Cash Flows Items
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 More detail:MOPS
 Foreign issuers’ information is disclosed in consolidated statements.